tetano
Editor, Senior Moderator
Hematol Oncol
. 2023 Dec 4.
doi: 10.1002/hon.3240. Online ahead of print. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry
Pellegrino Musto[SUP] 1 2 [/SUP], Jon Salmanton-García[SUP] 3 4 5 [/SUP], Nicola Sgherza[SUP] 2 [/SUP], Rui Bergantim[SUP] 6 [/SUP], Francesca Farina[SUP] 7 [/SUP], Andreas Glenthøj[SUP] 8 [/SUP], Guldane Cengiz Seval[SUP] 9 [/SUP], Barbora Weinbergerová[SUP] 10 [/SUP], Valentina Bonuomo[SUP] 11 12 [/SUP], Yavuz M Bilgin[SUP] 13 [/SUP], Jaap van Doesum[SUP] 14 [/SUP], Ozren Jaksic[SUP] 15 [/SUP], Benjamín Víšek[SUP] 16 [/SUP], Iker Falces-Romero[SUP] 17 18 [/SUP], Monia Marchetti[SUP] 19 [/SUP], Julio Dávila-Valls[SUP] 20 [/SUP], Sonia Martín-Pérez[SUP] 20 [/SUP], Marcio Nucci[SUP] 21 [/SUP], Alberto López-García[SUP] 22 [/SUP], Federico Itri[SUP] 23 [/SUP], Caterina Buquicchio[SUP] 24 [/SUP], Luisa Verga[SUP] 25 26 [/SUP], Klára Piukovics[SUP] 27 [/SUP], Milan Navrátil[SUP] 28 [/SUP], Graham P Collins[SUP] 29 [/SUP], Moraima Jiménez[SUP] 30 31 [/SUP], Nicola S Fracchiolla[SUP] 32 [/SUP], Jorge Labrador[SUP] 33 [/SUP], Lucia Prezioso[SUP] 34 [/SUP], Elena Rossi[SUP] 35 [/SUP], Natasha Čolović[SUP] 36 [/SUP], Stef Meers[SUP] 37 [/SUP], Austin Kulasekararaj[SUP] 38 39 [/SUP], Annarosa Cuccaro[SUP] 40 [/SUP], Ola Blennow[SUP] 41 [/SUP], Toni Valković[SUP] 42 43 [/SUP], Uluhan Sili[SUP] 44 [/SUP], Marie-Pierre Ledoux[SUP] 45 [/SUP], Josip Batinić[SUP] 46 47 [/SUP], Francesco Passamonti[SUP] 48 [/SUP], Marina Machado[SUP] 49 [/SUP], Rafael F Duarte[SUP] 50 [/SUP], Christian Bjørn Poulsen[SUP] 51 [/SUP], Gustavo-Adolfo Méndez[SUP] 52 [/SUP], Ildefonso Espigado[SUP] 53 [/SUP], Fatih Demirkan[SUP] 54 [/SUP], Martin Čerňan[SUP] 55 [/SUP], Chiara Cattaneo[SUP] 56 [/SUP], Verena Petzer[SUP] 57 [/SUP], Gabriele Magliano[SUP] 58 [/SUP], Carolina Garcia-Vidal[SUP] 59 [/SUP], Shaimaa El-Ashwah[SUP] 60 [/SUP], Maria Gomes-Da-Silva[SUP] 61 [/SUP], Antonio Vena[SUP] 62 63 [/SUP], Irati Ormazabal-Vélez[SUP] 64 [/SUP], Jens van Praet[SUP] 65 [/SUP], Michelina Dargenio[SUP] 66 [/SUP], Cristina De-Ramón[SUP] 67 68 [/SUP], Maria Ilaria Del Principe[SUP] 69 [/SUP], Joyce Marques-De-Almeida[SUP] 70 [/SUP], Dominik Wolf[SUP] 57 [/SUP], Tomáš Szotkowski[SUP] 71 [/SUP], Aleš Obr[SUP] 55 [/SUP], Gökçe Melis Çolak[SUP] 44 [/SUP], Anna Nordlander[SUP] 41 [/SUP], Macarena Izuzquiza[SUP] 30 31 [/SUP], Alba Cabirta[SUP] 30 [/SUP], Giovanni Paolo Maria Zambrotta[SUP] 25 26 [/SUP], Raul Cordoba[SUP] 22 [/SUP], Pavel Žák[SUP] 16 [/SUP], Emanuele Ammatuna[SUP] 14 [/SUP], Jiří Mayer[SUP] 10 [/SUP], Osman Ilhan[SUP] 9 [/SUP], Ramón García-Sanz[SUP] 68 72 [/SUP], Martina Quattrone[SUP] 35 [/SUP], Elena Arellano[SUP] 53 [/SUP], Raquel Nunes-Rodrigues[SUP] 61 [/SUP], Ziad Emarah[SUP] 60 [/SUP], Tommaso Francesco Aiello[SUP] 59 [/SUP], Michaela Hanakova[SUP] 73 [/SUP], Zdeněk Ráčil[SUP] 73 [/SUP], Martina Bavastro[SUP] 62 63 [/SUP], Alessandro Limongelli[SUP] 62 63 [/SUP], Laman Rahimli[SUP] 3 74 [/SUP], Francesco Marchesi[SUP] 75 [/SUP], Oliver A Cornely[SUP] 3 5 4 76 77 [/SUP], Livio Pagano[SUP] 35 [/SUP]
Affiliations
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 10[SUP]9[/SUP] /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.
Keywords: COVID-19; SARS-CoV-2; hematological malignancy; multiple myeloma.
. 2023 Dec 4.
doi: 10.1002/hon.3240. Online ahead of print. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry
Pellegrino Musto[SUP] 1 2 [/SUP], Jon Salmanton-García[SUP] 3 4 5 [/SUP], Nicola Sgherza[SUP] 2 [/SUP], Rui Bergantim[SUP] 6 [/SUP], Francesca Farina[SUP] 7 [/SUP], Andreas Glenthøj[SUP] 8 [/SUP], Guldane Cengiz Seval[SUP] 9 [/SUP], Barbora Weinbergerová[SUP] 10 [/SUP], Valentina Bonuomo[SUP] 11 12 [/SUP], Yavuz M Bilgin[SUP] 13 [/SUP], Jaap van Doesum[SUP] 14 [/SUP], Ozren Jaksic[SUP] 15 [/SUP], Benjamín Víšek[SUP] 16 [/SUP], Iker Falces-Romero[SUP] 17 18 [/SUP], Monia Marchetti[SUP] 19 [/SUP], Julio Dávila-Valls[SUP] 20 [/SUP], Sonia Martín-Pérez[SUP] 20 [/SUP], Marcio Nucci[SUP] 21 [/SUP], Alberto López-García[SUP] 22 [/SUP], Federico Itri[SUP] 23 [/SUP], Caterina Buquicchio[SUP] 24 [/SUP], Luisa Verga[SUP] 25 26 [/SUP], Klára Piukovics[SUP] 27 [/SUP], Milan Navrátil[SUP] 28 [/SUP], Graham P Collins[SUP] 29 [/SUP], Moraima Jiménez[SUP] 30 31 [/SUP], Nicola S Fracchiolla[SUP] 32 [/SUP], Jorge Labrador[SUP] 33 [/SUP], Lucia Prezioso[SUP] 34 [/SUP], Elena Rossi[SUP] 35 [/SUP], Natasha Čolović[SUP] 36 [/SUP], Stef Meers[SUP] 37 [/SUP], Austin Kulasekararaj[SUP] 38 39 [/SUP], Annarosa Cuccaro[SUP] 40 [/SUP], Ola Blennow[SUP] 41 [/SUP], Toni Valković[SUP] 42 43 [/SUP], Uluhan Sili[SUP] 44 [/SUP], Marie-Pierre Ledoux[SUP] 45 [/SUP], Josip Batinić[SUP] 46 47 [/SUP], Francesco Passamonti[SUP] 48 [/SUP], Marina Machado[SUP] 49 [/SUP], Rafael F Duarte[SUP] 50 [/SUP], Christian Bjørn Poulsen[SUP] 51 [/SUP], Gustavo-Adolfo Méndez[SUP] 52 [/SUP], Ildefonso Espigado[SUP] 53 [/SUP], Fatih Demirkan[SUP] 54 [/SUP], Martin Čerňan[SUP] 55 [/SUP], Chiara Cattaneo[SUP] 56 [/SUP], Verena Petzer[SUP] 57 [/SUP], Gabriele Magliano[SUP] 58 [/SUP], Carolina Garcia-Vidal[SUP] 59 [/SUP], Shaimaa El-Ashwah[SUP] 60 [/SUP], Maria Gomes-Da-Silva[SUP] 61 [/SUP], Antonio Vena[SUP] 62 63 [/SUP], Irati Ormazabal-Vélez[SUP] 64 [/SUP], Jens van Praet[SUP] 65 [/SUP], Michelina Dargenio[SUP] 66 [/SUP], Cristina De-Ramón[SUP] 67 68 [/SUP], Maria Ilaria Del Principe[SUP] 69 [/SUP], Joyce Marques-De-Almeida[SUP] 70 [/SUP], Dominik Wolf[SUP] 57 [/SUP], Tomáš Szotkowski[SUP] 71 [/SUP], Aleš Obr[SUP] 55 [/SUP], Gökçe Melis Çolak[SUP] 44 [/SUP], Anna Nordlander[SUP] 41 [/SUP], Macarena Izuzquiza[SUP] 30 31 [/SUP], Alba Cabirta[SUP] 30 [/SUP], Giovanni Paolo Maria Zambrotta[SUP] 25 26 [/SUP], Raul Cordoba[SUP] 22 [/SUP], Pavel Žák[SUP] 16 [/SUP], Emanuele Ammatuna[SUP] 14 [/SUP], Jiří Mayer[SUP] 10 [/SUP], Osman Ilhan[SUP] 9 [/SUP], Ramón García-Sanz[SUP] 68 72 [/SUP], Martina Quattrone[SUP] 35 [/SUP], Elena Arellano[SUP] 53 [/SUP], Raquel Nunes-Rodrigues[SUP] 61 [/SUP], Ziad Emarah[SUP] 60 [/SUP], Tommaso Francesco Aiello[SUP] 59 [/SUP], Michaela Hanakova[SUP] 73 [/SUP], Zdeněk Ráčil[SUP] 73 [/SUP], Martina Bavastro[SUP] 62 63 [/SUP], Alessandro Limongelli[SUP] 62 63 [/SUP], Laman Rahimli[SUP] 3 74 [/SUP], Francesco Marchesi[SUP] 75 [/SUP], Oliver A Cornely[SUP] 3 5 4 76 77 [/SUP], Livio Pagano[SUP] 35 [/SUP]
Affiliations
- PMID: 38050405
- DOI: 10.1002/hon.3240
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 10[SUP]9[/SUP] /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.
Keywords: COVID-19; SARS-CoV-2; hematological malignancy; multiple myeloma.